secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001104659-25-047304
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome Q1 net loss $41.6M; cash $317.3M; varegacestat data expected H2 2025
-----------------------------------------------------------------------------

- Net loss of $41.6M for Q1 2025; R&D expense $36.9M, G&A $10.7M.
- Cash, equivalents and marketable securities $317.3M as of March 31, 2025; expected to fund operations into 2027.
- Phase 3 RINGSIDE trial of varegacestat fully enrolled; topline data expected in second half of 2025.
- Phase 1 for IM-1021 (ROR1 ADC) ongoing; IM-3050 (FAP radiotherapy) IND cleared, trial to start H2 2025.
- Amended 2024 Inducement Plan to increase reserved shares from 2M to 3.5M for new-hire equity grants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465925047304/0001104659-25-047304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465925047304/tm2514592d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-047304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer